The endovascular occlusion system for safe and immediate peripheral vessel occlusion during vascular interventions by Emmert, Maximilian Y et al.
The endovascular occlusion system for safe and immediate peripheral
vessel occlusion during vascular interventions
Maximilian Y. Emmerta,b,*, Anthony Venbruxc, Leon Rudakovd, Nikola Cesarovicb, Martin G. Radvanye,
Philippe Gailloude, Volkmar Falka and Andre Plassa
a Clinic for Cardiac and Vascular Surgery, University Hospital Zurich, Zurich, Switzerland
b Division of Surgical Research, University Hospital of Zurich, Zurich, Switzerland
c Division of Vascular and Interventional Radiology, George Washington University, DC, WA, USA
d ArtVentive Medical Group, Inc., Carlsbad, CA, USA
e Division of Interventional Neuroradiology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
* Corresponding author. Clinic for Cardiac and Vascular Surgery, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland. Tel: +41-44-2551111;
E-mail: maximilian.emmert@usz.ch (M.Y. Emmert).
Received 1 May 2013; received in revised form 17 June 2013; accepted 24 June 2013
Abstract
Endovascular occlusion of blood vessels is an important part of interventional therapy concepts. Here, we evaluate the feasibility, proced-
ural safety and efficacy of the novel endovascular occlusion system (EOS) in the arterial system in a porcine model. Thirteen devices were
deployed in the iliac and femoral arteries (diameter: 4–5 mm) of five adult swine. Post-deployment angiography was performed at 1, 5
and 10 min and 6 h. All devices (n = 13) could be successfully delivered without any complications, such as dissection, perforation or
rupture. The devices could be easily advanced to the target vessel segment, deployed at the intended target location and produced imme-
diate and complete vessel occlusion which was confirmed to be maintained after 6 h. No leaks, recanalization or device migration was
observed. In this pilot study, we demonstrate the feasibility, safety and efficacy of immediate vessel occlusion with the EOS device in the
peripheral arterial system in a porcine animal model. Our data indicate that this novel device allows precise delivery without the occur-
rence of cardiovascular complications. Owing to its long-term safety and efficacy the EOS may represent a promising and effective alterna-
tive to currently available devices for vessel occlusion during vascular interventions.
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INTRODUCTION
Endovascular occlusion of blood vessels is an essential aspect of
interventional vascular therapy concepts [1–3]. However, immedi-
ate and durable vessel occlusion remains a challenge when using
the currently available devices and may often necessitate use of a
large number of devices as well as long interventional procedures
with high radiation exposure. In the present study, we assess a
novel endoluminal occlusion system (EOS) for transcatheter vessel
occlusion in the peripheral arterial system and demonstrate tech-
nical feasibility and procedural safety in a porcine model.
MATERIALS ANDMETHODS
Device description
The EOS (ArtVentive Medical Group, Inc., Carlsbad, CA, USA) device
allows percutaneous occlusion of the peripheral arterial and venous
vasculature. The EOS system is comprised of an implant carrier
catheter with a preloaded self-expandable implant and a guide
sheath with a removable core (Fig. 1A–E). The EOS implant is made
of a Nitinol scaffold covered with an impermeable expanded
Polytetrafluorethylen membrane, which is composed to maintain
complete impermeability in order to occlude blood flow reliably,
precisely and immediately. The scaffold design is based on a flat
helical structure. The EOS implant is available in two sizes: 6 mm for
treatment of vessels between 3.0 and 4.8 mm in diameter, and
9 mm for treatment of vessels between 4.5 and 7.8 mm in diam-
eter, with a calculated oversizing of at least 15%. It generates suffi-
cient radial force to provide good vessel wall apposition and to
minimize post-deployment migration (Fig. 1A–E). The device
design generates low local pressure that lowers the risk of vessel
damage and rupture. The device is self-expandable and highly flex-
ible per design. It is also highly adoptable to the vessel geometry.
Therefore, it actually adopts the vessel configuration as every
segment of the device along its length takes shape of target vessel.
The device maximum length as deployed is <20 mm. The delivery
mechanism and the steps of delivery are summarized in Fig. 1B–E.
The device is delivered via a 6-Fr guide sheath. The guide sheath is
advanced using a 0.035 guide wire.
Animal study
To assess the acute safety and technical feasibility of the EOS, 13
devices (11 × 6 mm and 2 × 9 mm) were tested in the preclinical
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setting and deployed in the iliac and femoral arteries of five adult
female Landrace swine (67 ± 3 kg).
Animal care and anaesthesia
All procedures were approved by the Institutional Ethics
Committee (Cantonal Veterinary Office, license no. 138/2010), and
all animals received humane care in compliance with the ‘Principles
of Laboratory Animal Care’ and according to the ‘Guide to the Care
and Use of Experimental Animals’ published by the US National
Institutes of Health. The adult swine (n = 5) were fasted overnight
prior to the procedure. Anaesthesia induction was performed with
an intramuscular injection of ketamine (20 mg/kg), azaperone
(2 mg/kg) and atropine (0.04 mg/kg). Anaesthesia was deepened
with bolus injection of propofol (1–3 mg/kg) intravenously, and
the animals were then intubated. Anaesthesia was maintained
with inhaled isoflurane (1–3%) in 50% oxygen. For intraoperative
analgesia, buprenorphine (Temgesic; 0.005 mg/kg) was used.
Device delivery and vessel occlusion
Prior to the procedures, the animals were placed in the supine
position, and an 8-Fr sheath surgically introduced in one of the
carotid arteries. All procedures were carried out in an animal
hybrid operation suite using a Philips Allura FD 20/20 Imaging
System. Predeployment angiography with three-dimensional (3D)
vessel reconstruction analysis was performed to define the target
vessel diameter and to determine the optimal size of the EOS
device. A corresponding post-deployment angiogram was per-
formed directly after the procedure (at 1, 5 and 10 min) as well as
6 h later to assess the acute safety and efficacy of the EOS device.
Under fluoroscopic guidance, the ArtVentive guide catheter was
introduced through the sheath and advanced into the target vessel
segment of the left or right iliac or femoral arteries. Thereafter, pre-
deployment angiography along with 3D reconstruction and sub-
traction analysis was performed to assess the vasculature and to
determine the vessel diameter. In total, 13 devices were used, with
nominal diameters of 6 mm (n = 11) or 9 mm (n = 2). In addition, a
roadmap image was acquired and used throughout device delivery
and deployment. To deploy the EOS, the device was introduced
into the delivery catheter, and advanced to its tip. The catheter
was then withdrawn, leaving the device unsheathed but still un-
deployed, at the target vessel segment. Finally, the EOS device was
deployed and detached utilizing a controlled, two-step release
mechanism (with the proximal end opening prior to the distal end).
RESULTS
All EOS devices (n = 13) were successfully delivered into the
intended segments of the left and right iliac arteries of the animals
Figure 1: EOS device, illustration of the EOS occlusion mechanism and angiography before and after EOS device deployment. EOS device shown in deployed config-
uration (A). The EOS is delivered through the guide sheath into the target position of the vessel (B) before the EOS device is unsheathed for deployment (C). The de-
ployment process is initiated by release of the proximal end (Step 1). At this stage, the operator is still in full control to refine the exact target position (D). Finally, the
distal end of the implant is deployed (Step 2), leading to immediate vessel occlusion. Thereafter, the carrier catheter can be easily removed (E). Predeployment angi-
ography was performed to define the target vessel and to assess the vessel diameter to determine the optimal EOS device size (F). After deployment of the EOS
device, immediate and complete vessel occlusion was achieved (G)
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and produced immediate and complete vessel occlusion (Fig. 1F
and G; Supplementary Video 1). There were no major or minor
complications, such as vascular dissection, perforation or rupture
along the arterial access path or at the site of EOS delivery. In par-
ticular, all EOS devices could be easily introduced into the delivery
catheter, advanced to the target vessel segment and deployed
at the intended target location. Post-deployment angiography at
1 min showed immediate and complete vessel occlusion, which
was confirmed at the 5- and 10-min angiography. At the 6-h post-
implantation angiography, complete occlusion could be shown
to be maintained and importantly, there were no signs of acute
migration of the EOS device, leaks and recanalization. Table 1
summarizes the procedural and outcome data.
DISCUSSION
Endovascular vessel occlusion represents an important aspect of
interventional therapy strategies for a wide range of vascular and
non-vascular conditions [1–3]. However, the currently available
strategies have been reported to come with a limited efficacy with
regard to a complete and durable vessel occlusion. While coils
have been commonly used for vessel occlusion, a large number of
these devices may be necessary to achieve complete occlusion
and to minimize the risk of recanalization. To overcome these lim-
itations, new devices have been developed [4–6]; however, some
of these devices require large delivery sheaths and catheters [7],
have complicated delivery systems and do not always achieve a
fast and durable vessel occlusion [8–10].
Here, we introduce a novel endoluminal occlusion system for
transcatheter vessel occlusion. Our results demonstrate the feasi-
bility and safety of immediate vessel occlusion in the arterial
system with the EOS device in an acute porcine model. Our data
indicate that this novel device allows precise delivery and deploy-
ment at the intended location site without the occurrence of car-
diovascular complications, such as dissection, perforation or
rupture. Due to its simple and efficient design, the EOS device
technology is multifaceted and thus may have other indications in
the venous and arterial system of different body regions. While
this was a pilot study focusing on technical feasibility, procedural
safety and acute efficacy, long-term data and comparative studies
of other devices are necessary. Its long-term safety and efficacy
proven, the EOS may represent a promising and effective alterna-
tive to currently available devices for vessel occlusion during vas-
cular interventions.
SUPPLEMENTARYMATERIAL
Supplementary material is available at ICVTS online.
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